Krystal Biotech
![Krystal's Vyjuvek Gene Therapy Receives FDA Approval, Boosts Sales Forecast](https://pharmtales.com/wp-content/uploads/2023/11/Krystals-Vyjuvek-Gene-Therapy-Gains-FDA-Approval-Spurs-Sales-Projections.jpg)
Krystal’s Vyjuvek Gene Therapy Gains FDA Approval, Spurs Sales Projections
Anika Sharma
Krystal Biotech’s CEO, Krish Krishnan, was quick to highlight in the company’s inaugural conference call to present its quarterly results ...
![Krystal Biotech, Priority Review Voucher, Vyjuvek, Beremagene geperpavec-svdt, Rare Pediatric Disease](https://pharmtales.com/wp-content/uploads/2023/08/Krystal-Biotech-Secures-100-Million-in-Sale-of-Priority-Review-Voucher.jpg)
Krystal Biotech Secures $100 Million in Sale of Priority Review Voucher
Anika Sharma
Krystal Biotech proudly announces the successful transaction of its Rare Pediatric Disease Priority Review Voucher (PRV), yielding an impressive $100 ...